Ivermectin buy online, an antiparasitic drug, gained attention for potential COVID-19 treatment. Lab studies suggested it might inhibit SARS-CoV-2 replication by interfering with viral proteins. Early observational and small clinical studies hinted at benefits, prompting widespread off-label use. However, large-scale, randomized controlled trials later found no significant improvement in COVID-19 outcomes with ivermectin compared to standard care. Major health organizations, including the WHO and FDA, advise against using ivermectin for COVID-19 outside of clinical trials due to insufficient evidence of efficacy and safety concerns. The initial promise seen in vitro didn't translate into clinical success, underscoring the need for rigorous trials before adopting treatments for new diseases.
